Redmile Group, LLC — 13F Holdings & Portfolio
CIK 1425738 · latest 13F-HR filed 2026-08-14
Redmile Group, LLC manages $1.49B in 13F-reported U.S. long-equity assets across 39 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are SRRK (15.92%), KRYS (15.77%), STOK (8.67%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 4 new positions, exited 0, added to 18, and trimmed 14.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 270
LARKSPUR, CA 94939
$1.49B
Long-equity book
39
Distinct positions
2026-06-30
Filed 2026-08-14
+4 / −0 / ↑18 / ↓14
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- KRYSTAL BIOTECH INC$60.9M +35.0%
- ABSCI CORPORATION$53.4M +215.5%
- AGOMAB THERAPEUTICS NV$33.8M +2065.0%
- FATE THERAPEUTICS INC$19.3M +125.0%
- REGENXBIO INC$15.7M +43.0%
Top Trims
- SCHOLAR ROCK HLDG CORP-$208.6M -46.8%
- ADC THERAPEUTICS SA-$45.7M -78.7%
- NURIX THERAPEUTICS INC-$21.0M -17.5%
- IMMUNOME INC-$17.5M -14.4%
- ANNEXON INC-$12.8M -15.9%
New Positions
- CLIMB BIO INC$16.0M
- AURA BIOSCIENCES INC$11.8M
- ODYSSEY THERAPEUTICS INC$8.0M
- INSMED INC$5.5M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $237.1M | 15.92% | 4,311,092 | SH |
| 2 | KRYSTAL BIOTECH INC | KRYS | 501147102 | $234.9M | 15.77% | 632,005 | SH |
| 3 | STOKE THERAPEUTICS INC | STOK | 86150R107 | $129.1M | 8.67% | 3,945,920 | SH |
| 4 | IMMUNOME INC | IMNM | 45257U108 | $104.1M | 6.99% | 4,911,590 | SH |
| 5 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $98.8M | 6.64% | 4,073,787 | SH |
| 6 | ABSCI CORPORATION | ABSI | 00091E109 | $78.1M | 5.24% | 6,739,675 | SH |
| 7 | ANNEXON INC | ANNX | 03589W102 | $67.8M | 4.55% | 11,869,877 | SH |
| 8 | REGENXBIO INC | RGNX | 75901B107 | $52.3M | 3.51% | 4,368,804 | SH |
| 9 | SHATTUCK LABS INC | STTK | 82024L103 | $47.8M | 3.21% | 6,892,033 | SH |
| 10 | NEUROGENE INC | NGNE | 64135M105 | $44.4M | 2.98% | 1,412,199 | SH |
| 11 | BEAM THERAPEUTICS INC | BEAM | 07373V105 | $40.0M | 2.68% | 1,164,259 | SH |
| 12 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $35.5M | 2.38% | 2,733,926 | SH |
| 13 | FATE THERAPEUTICS INC | FATE | 31189P102 | $34.8M | 2.33% | 12,872,946 | SH |
| 14 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $23.9M | 1.60% | 640,202 | SH |
| 15 | SILENCE THERAPEUTICS PLC | SLN | 82686Q101 | $23.8M | 1.60% | 2,164,777 | SH |
| 16 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $19.5M | 1.31% | 503,321 | SH |
| 17 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $19.5M | 1.31% | 1,948,695 | SH |
| 18 | NUVATION BIO INC | NUVB | 67080N101 | $17.2M | 1.16% | 3,031,009 | SH |
| 19 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $16.1M | 1.08% | 433,921 | SH |
| 20 | CLIMB BIO INC | CLYM | 28658R106 | $16.0M | 1.07% | 1,226,330 | SH |
| 21 | ALX ONCOLOGY HLDGS INC | ALXO | 00166B105 | $15.3M | 1.03% | 7,392,504 | SH |
| 22 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $15.2M | 1.02% | 265,169 | SH |
| 23 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $13.8M | 0.93% | 229,374 | SH |
| 24 | ZYMEWORKS INC | ZYME | 98985Y108 | $12.9M | 0.86% | 491,654 | SH |
| 25 | ADC THERAPEUTICS SA | ADCT | H0036K147 | $12.3M | 0.83% | 11,526,710 | SH |
| 26 | AURA BIOSCIENCES INC | AURA | 05153U107 | $11.8M | 0.79% | 1,666,667 | SH |
| 27 | ODYSSEY THERAPEUTICS INC | ODTX | 67613T104 | $8.0M | 0.53% | 425,000 | SH |
| 28 | LIVANOVA PLC | LIVN | G5509L101 | $7.7M | 0.51% | 93,154 | SH |
| 29 | ESTABLISHMENT LABS HLDGS INC | ESTA | G31249108 | $7.6M | 0.51% | 88,964 | SH |
| 30 | CERIBELL INC | CBLL | 15678C102 | $7.5M | 0.51% | 386,786 | SH |
| 31 | DBV TECHNOLOGIES S A | DBVT | 23306J309 | $6.7M | 0.45% | 410,440 | SH |
| 32 | INSMED INC | INSM | 457669307 | $5.5M | 0.37% | 51,234 | SH |
| 33 | PRIME MEDICINE INC | PRME | 74168J101 | $5.1M | 0.34% | 1,389,632 | SH |
| 34 | ATARA BIOTHERAPEUTICS INC | ATRA | 046513206 | $5.1M | 0.34% | 441,701 | SH |
| 35 | EUPRAXIA PHARMACEUTICALS INC | EPRX | 29842P105 | $4.0M | 0.27% | 611,400 | SH |
| 36 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $3.9M | 0.26% | 362,010 | SH |
| 37 | ARDELYX INC | ARDX | 039697107 | $3.3M | 0.22% | 641,750 | SH |
| 38 | INVIVYD INC | IVVD | 00534A102 | $2.3M | 0.15% | 2,597,759 | SH |
| 39 | PLIANT THERAPEUTICS INC | PLRX | 729139105 | $880.2K | 0.06% | 772,126 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.49B | 39 | 0001104659-26-097182 |
| 2026-03-31 | 2026-05-15 | $1.51B | 35 | 0001104659-26-062579 |
| 2025-12-31 | 2026-02-17 | $1.36B | 34 | 0001104659-26-016433 |
| 2025-09-30 | 2025-11-14 | $1.03B | 40 | 0001104659-25-112572 |